InspireMD (NSPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, with voting available online or in person in Tel Aviv, Israel.
Shareholders are encouraged to review proxy materials and vote by June 2, 2026.
Voting matters and shareholder proposals
Election of three Class III directors for three-year terms: Marvin Slosman, Raymond Cohen, and Dan Dearen, all recommended by the board.
Proposal to amend the Certificate of Incorporation to increase authorized common stock from 150,000,000 to 250,000,000.
Ratification of Kesselman & Kesselman as independent auditors for the year ending December 31, 2026.
Approval to adjourn the meeting if necessary to solicit more votes for the main proposals.
Board of directors and corporate governance
Board recommends all director nominees for election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from InspireMD
- Q2 2026 saw flat revenue, a wider net loss, and a major cost-saving workforce reduction amid going concern risks.NSPR
Q2 2026 - Endovascular stenting for carotid disease is accelerating, backed by best-in-class clinical results.NSPR
Bank of America Global Healthcare Conference 2026 - CGuard® Prime leverages clinical leadership and innovation to capture a growing carotid stenting market.NSPR
Investor presentation - Q1 revenue up 122% year-over-year; net loss widened and FDA approvals expected to drive growth.NSPR
Q1 2026 - Routine proposals allow brokers to vote uninstructed shares on key capital and auditor matters.NSPR
Proxy filing - Proxy seeks approval for director elections, share increase, auditor ratification, and meeting adjournment.NSPR
Proxy filing - Innovative stent and CMS changes accelerate a stent-first shift in carotid intervention.NSPR
25th Annual Needham Virtual Healthcare Conference - Q4 revenue up 62% to $3.1M; 2026 outlook strong with up to 65% growth and $54.2M cash.NSPR
Q4 2025 - Net loss widened on higher expenses as FDA approval for CGuard Prime is anticipated in Q3 2025.NSPR
Q1 2025